Systemic inflammatory response syndrome

Parker, 1983, Septic shock. Hemodynamics and pathogenesis, JAMA, 250, 3324, 10.1001/jama.1983.03340240050031

Bone, 1992, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine, Chest, 101, 1644, 10.1378/chest.101.6.1644

Rangel-Frausto, 1995, The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study, JAMA, 273, 117, 10.1001/jama.1995.03520260039030

Salvo, 1995, The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock, Intensive Care Med, 21, S244-9, 10.1007/BF01740762

Pittet, 1995, Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients, Intensive Care Med, 21, 302, 10.1007/BF01705408

Smail, 1995, Role of systemic inflammatory response syndrome and infection in the occurrence of early multiple organ dysfunction syndrome following severe trauma, Zntensive Care Med, 21, 813, 10.1007/BF01700964

Baker, 1995, Sepsis in the critically ill patient, Curr Probl Surg, 32, 1015, 10.1016/S0011-3840(05)80018-8

Collins, 1978, Cellular antimicrobial immunity, CRC Critical Review in Microbiology, 7, 27, 10.3109/10408417909101177

Dantzker, 1989, Oxygez delivery and utilization in sepsis, Crit Care Clin, 5, 81, 10.1016/S0749-0704(18)30451-2

Dantzker, 1991, Oxygen supply and utilization relationships. A reevaluation, American Review Respiratory Diseases, 143, 675, 10.1164/ajrccm/143.3.675

Tuchschmidt, 1992, Elevation of cardiac output and oxygen delivery improves outcomes in septic shock, Chest, 102, 216, 10.1378/chest.102.1.216

Slotman, 1986, Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension, Surgery, 99, 744

Bone, 1996, Toward a theory regarding the pathogenesis of the systemic inflammatory response system: what we do and do not know about cytokine regulation, Crit Care Med, 24, 163, 10.1097/00003246-199601000-00026

Quezado, 1992, Systemic hemodynamic abnormalities and vasopressor therapy in sepsis and septic shock, Am J Kidney Dis, 20, 214, 10.1016/S0272-6386(12)80693-7

Suffredini, 1992, Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans, American Review Respiratory Diseases, 145, 1398, 10.1164/ajrccm/145.6.1398

Hinshaw, 1996, Sepsidseptic shock: participation of the microcirculation: an abbreviated review, Crit Care Med, 24, 1072, 10.1097/00003246-199606000-00031

Graves, 1995, Chemokines: a family of chemotactic cytokines, Crit Rev Oral Biol Med, 6, 109, 10.1177/10454411950060020101

Van der Poll, 1990, Activation of coagulation after administration of tumor necrosis factor to normal subjects, N Engl J Med, 322, 1622, 10.1056/NEJM199006073222302

Jansen, 1995, Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degradation, and the release of secretory-type phospholipase Az in sepsis: studies in nonhuman primates after interleukin-l a administration and during lethal bacteremia, Blood, 86, 1027, 10.1182/blood.V86.3.1027.1027

Kalter, 1983, Activation of purified human plasma prekallikrein trigggered by cell wall fractions of Escherichia coli and Staphylococcus aureus, J Infect Dis, 148, 682, 10.1093/infdis/148.4.682

Warr, 1990, Disseminated intravasacular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity, Blood, 75, 1481, 10.1182/blood.V75.7.1481.1481

Suffredini, 1989, Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects, N Engl J Med, 320, 1165, 10.1056/NEJM198905043201802

Gando, 1995, Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome, Thromb Res, 80, 519, 10.1016/0049-3848(95)00207-3

Fourrier, 1992, Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin 111, protein C, and protein S deficiencies, Chest, 101, 816, 10.1378/chest.101.3.816

Gando, 1996, Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome, Thromb Haemost, 75, 224, 10.1055/s-0038-1650248

Souba, 1994, Cytokine control of nutrition and metabolism in critical illness, Cur Probl Surg, 31, 577

Munchie, 1988, Detection of circulating tumor necrosis factor after endotoxin administration, N Engl J Med, 318, 1481, 10.1056/NEJM198806093182301

Waage, 1989, The complex pattern of cytokines in serum with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome, J Exp Med, 169, 10.1084/jem.169.1.333

Pinsky, 1993, Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality, Chest, 103, 565, 10.1378/chest.103.2.565

Waage, 1987, Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease, Lancet, i, 355, 10.1016/S0140-6736(87)91728-4

Tracey, 1987, Anti-cachectinDNF monoclonal antibodies prevent septic shock during lethal bacteraemia, Nature, 330, 662, 10.1038/330662a0

Suffredini, 1989, The cardiovascular response of normal humans to the administration of endotoxin, N Engl J Med, 321, 280, 10.1056/NEJM198908033210503

Goldie, 1995, Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group, JAM, 274, 172, 10.1001/jama.1995.03530020090038

Hack, 1989, Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis, Am J Med, 86, 20, 10.1016/0002-9343(89)90224-6

Ognibene, 1988, Neutrophil aggregation activity and septic shock in humans: neutrophil aggregation by a C5a-like material occurs more frequently than complement component depletion and correlates with demession of svstemic vascular resistance, Journal of Critical Care, 3, 103, 10.1016/0883-9441(88)90042-1

Slotman, 1986, Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension, Surgery, 99, 744

Pixley, 1995, Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome, Crit Care Med, 23, 41, 10.1097/00003246-199501000-00010

Yentis, 1995, C-reactive protein as an indicator of resolution of sepsis in the intensive care unit, Intensive Care Med, 21, 602, 10.1007/BF01700168

Tobias, 1988, A family of lipopolysaccharide binding proteins involved in responses to Gram-negative sepsis, J Biol Chem, 263, 13479, 10.1016/S0021-9258(18)68262-6

Tobias, 1986, Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum, J Exp Med, 164, 777, 10.1084/jem.164.3.777

Schumann, 1990, Structure and function of lipopolysaccharide binding protein, Science, 249, 1429, 10.1126/science.2402637

Opal, 1991, Bactericidal/permeability-increasing protein as a novel therapeutic modality in the treatment of endotoxic shock, Clin Res, 39, 351A

Parsons, 1995, Neutrophil response to endotoxin in the adult respiratory distress syndrome: role of CD14, Am J Respir Cell Mol Biol, 13, 152, 10.1165/ajrcmb.13.2.7542895

Fong, 1990, The biologic characteristics of cytokines and their implication in surgical injury, Surg Gynecol Obstet, 170, 363

Tsujimoto, 1986, Tumor necrosis factor receptors in HeLa cells and their regulation by interferon-gamma, J Biol Chem, 261, 5384, 10.1016/S0021-9258(19)57227-1

Aggamal, 1985, Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon, Nature, 318, 665, 10.1038/318665a0

Okusawa, 1988, Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition, J Clin hvest, 81, 1162, 10.1172/JCI113431

Tracey, 1986, Shock and tissue injury induced by recombinant human cachectin, Science, 234, 470, 10.1126/science.3764421

Beutler, 1985, Passive immunization against cachectinltumor necrosis factor protects mice from lethal effect of endotoxin, Science, 229, 869, 10.1126/science.3895437

Kawakami, 1981, Studies of endotoxin-induced decrease in lipoprotein lipase activity, J Exp Med, 154, 631, 10.1084/jem.154.3.631

Dinarello, 1984, Interleukin-1, Reviews of Infectious Diseuses, 6, 51, 10.1093/clinids/6.1.51

Pruitt, 1995, Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock, Shock, 3, 235, 10.1097/00024382-199504000-00001

March, 1985, Cloning sequence and expression of two distinct human interleukin-1 complementary DNA, Nature, 315, 641, 10.1038/315641a0

Giri, 1994, Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses, J Immunol, 153, 5802, 10.4049/jimmunol.153.12.5802

Fong, 1989, Endotoxemia elicits increased circulating beta 2–IFN/IL-6 in man, J Immunol, 142, 2321, 10.4049/jimmunol.142.7.2321

Nawroth, 1986, Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity, Proc Natl Acad Sci USA, 83, 2460, 10.1073/pnas.83.10.3460

May, 1989, Synthesis and secretion of multiple forms of ‘beta 2 interferonm cell differentiation factor BSF−2 hepatocyte stimulating factor’ by human fibroblasts and monocytes, J Biol Chem, 263, 7760, 10.1016/S0021-9258(18)68564-3

Fong, 1989, Antibodies to cachectin/tumor necrosis factor reduce interleukin-lß and interleukin-6 appearance during lethal bacteremia, J Exp Med, 170, 10.1084/jem.170.5.1627

Starnes, 1990, Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-a challenge in mice, J Immunol, 145, 4185, 10.4049/jimmunol.145.12.4185

Harada, 1994, Essential involvement of interleukin-8 (IL-8) in acute inflammation, J Leukoc Biol, 56, 559, 10.1002/jlb.56.5.559

Davies, 1993, The vascular endothelium. A new horizon, Ann Surg, 218, 593, 10.1097/00000658-199321850-00003

Eisenberg, 1991, Endothelial cell mediators of thrombosis and fibrinolysis: Review in depth, Coronary Artery Diseases, 2, 129, 10.1097/00019501-199104000-00001

Ley, 1992, Leukocyte adhesion to vascular endothelium, J Reconstr Microsurg, 8, 495, 10.1055/s-2007-1006736

Fujishima, 1995, Neutrophil-mediated tissue injury and its modulation, Intensive Care Med, 21, 277, 10.1007/BF01701489

Rosenbloom, 1995, Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction, JAMA, 274, 58, 10.1001/jama.1995.03530010072037

Cluzel, 1989, Release of platelet-activating factor and the metabolism of leukotriene B, by the human neutrophil when studied in a cell superfusion model, J Immunol, 143, 3659, 10.4049/jimmunol.143.11.3659

Bussolino, 1985, Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells, J Immunol, 135, 2748, 10.4049/jimmunol.135.4.2748

Pereira, 1995, CAP37, a neutrophil-derived multifunctional inflammatory mediator, J Leukoc Biol, 57, 805, 10.1002/jlb.57.6.805

Ahmed, 1996, Expression of human neutrophil L-selectin during the systemic inflammatory response syndrome is partly mediated by tumor necrosis factor a, Arch Surg, 131, 31, 10.1001/archsurg.1996.01430130033006

Gawaz, 1995, Platelet activation and interaction with leukocytes in patients with sepsis or multiple organ failure, Eur J Clin Invest, 25, 843, 10.1111/j.1365-2362.1995.tb01694.x

Haj, 1995, Influence of white blood cells on the fibrinolytic responses to sepsis: studies of septic patients with and without severe leucopenia, Br J Huematol, 90, 541, 10.1111/j.1365-2141.1995.tb05581.x

Ridings, 1995, A dual-binding antibody to E and L-selectin attenuates sepsis-induced lung injury, Am J Respir Crit Care Med, 152, 247, 10.1164/ajrccm.152.1.7541277

Ridings, 1995, Sepsis-induced acute lung injury is attenuated by selectin blockade following the onset of sepsis, Arch Surg, 130, 1199, 10.1001/archsurg.1995.01430110057011

Cybulsky, 1991, Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis, Science, 251, 788, 10.1126/science.1990440

Cushing, 1992, Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein, Arteriosclerosis and Thrombosis, 12, 78, 10.1161/01.ATV.12.1.78

Yla-Hettuala, 1991, Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions, Proc Natl Acad Sci USA, 88, 5252, 10.1073/pnas.88.12.5252

Nelken, 1991, Monocyte chemoattractant protein-1 in human atheromatous plaques, J Clin Invest, 88, 1121, 10.1172/JCI115411

Wang, 1991, Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated vascular smooth muscle cells, Arteriosclerosis and Thrombosis, 11, 1166, 10.1161/01.ATV.11.5.1166

Sporn, 1990, Monocyte adherence results in selective induction of novel genes sharing homology with mediators of inflammation and tissue repair, J Immunol, 144, 4434, 10.4049/jimmunol.144.11.4434

Nelson, 1992, Interleukin-2 and the regulation of activated macrophage cytotoxic activities, Adv Exp Med Biol, 319, 77, 10.1007/978-1-4615-3434-1_9

Unanue, 1987, The basis for the immunoregulatory role of macrophages and other accessory cells, Science, 236, 551, 10.1126/science.2437650

Nussler, 1993, Inflammation, immunoregulation, and inducible nitric oxide synthase, J Leukoc Biol, 54, 171, 10.1002/jlb.54.2.171

Wolfe, 1995, Use of nitric oxide synthase inhibitors as a novel treatment for septic shock, Ann Pharmacother, 29, 36, 10.1177/106002809502900108

Nathan, 1991, Role of nitric oxide synthesis in macrophage antimicrobial activity, Curr Opin Immunol, 3, 65, 10.1016/0952-7915(91)90079-G

Thiemermann, 1994, The role of the L-arginine-nitric oxide pathway in circulatory shock, Adv Pharmacol, 28, 45, 10.1016/S1054-3589(08)60493-7

Morris, 1994, New insights into the regulation of inducible nitric oxide synthesis, Am J Physiol, 266, E829-39

Brady, 1993, Circulatory failure in septic shock. Nitric oxide: too much of a good thing, ? Brit Heart J, 70, 103, 10.1136/hrt.70.2.103

Finkel, 1992, Negative inotropic effects of cytokines on the heart mediated by nitric oxide, Science, 257, 387, 10.1126/science.1631560

Goode, 1995, Nitric oxide synthase activity is increased in patients with sepsis syndrome, Clin Sci, 88, 131, 10.1042/cs0880131

Nava, 1991, Inhibition of nitric oxide synthesis in septic shock: how much is beneficial?, Lancet, 338, 1555, 10.1016/0140-6736(91)92375-C

Kilbourn, 1990, Gross SS. Jubran A et al. N-methvl L-areinine inhibits tumor necrosis factor-induced hypotekon: implications for the involvement of nitric oxide, Proc Ntl AcadSci USA, 87, 3629, 10.1073/pnas.87.9.3629

Pastor, 1994, Effects of l-arginine and L-nitro-arginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model, Cnt Care Med, 22, 465, 10.1097/00003246-199403000-00017

Petros, 1991, Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock, Lancet, 338, 1557, 10.1016/0140-6736(91)92376-D

Geroulanos, 1992, Inhibition of NO synthesis in septic shock, Lancet, 339, 435

Hibbs, 1989, Nitric oxide: a cytotoxic activated macrophage effector molecule, Biochem Biophys Res Commun, 157, 87, 10.1016/S0006-291X(88)80015-9

Moncada, 1991, Nitric oxide: physiology, pathophysiology, and pharmacology, Pharmacol Rev, 43, 109

Katusic, 1989, Superoxide anion is an endothelium-derived contracting factor, Am J Physiol, 257, H33-7

Rubanyi, 1988, Vascular effects of oxygen-derived free radicals, Free Radic Biol Med, 4, 107, 10.1016/0891-5849(88)90071-8

Haglund, 1991, Oxygen-free radicals (OFR) and circulatory shock, Circ Shock, 34, 405

Conner, 1996, Inflammation, free radicals, and antioxidants, Nutrition, 12, 274, 10.1016/S0899-9007(96)00000-8

Lucchesi, 1994, Complement, neutrophils and free radicals: mediators of reperfusion injury, Arznei-mittelforschung, 44, 420

Swank, 1989, Roles of the neutrophil and mediators in adult respiratory distress syndrome, Mayo Clin Proc, 64, 1118, 10.1016/S0025-6196(12)64981-7

Bernard, 1991, N-acetylcysteine in experimental and clinical acute lung injury, Am J Med, 91, 54, 10.1016/0002-9343(91)90284-5

Sun, 1988, Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor, J Clin Invest, 81, 1328, 10.1172/JCI113459

Touvay, 1988, Role of platelet-activating factor (PAF) in the bronchopulmonary alterations and beta-adrenoceptor function induced by endotoxin, Biochem Biophys Res Commun, 152, 527, 10.1016/S0006-291X(88)80069-X

Moore, 1991, A PAF antagonist BN 52021, attenuates thromboxane release and imroves survival in lethal canine endotoxemia, Circ Shock, 35, 53

Yue, 1990, Protective effect of BN50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits, J Phamacol Exp Ther, 254, 976

McClave, 1992, Immunonutrition and enteral hyperalimentation of critically ill patients, Dig Dis Sci, 37, 1153, 10.1007/BF01296554

Ziegler, 1994, Strategies for attenuating protein-catabolic responses in the critically ill, Annu Rev Med, 45, 459, 10.1146/annurev.med.45.1.459

McMahon, 1993, Nutritional support of critically ill patients, Mayo Clin Proc, 68, 911, 10.1016/S0025-6196(12)60702-2

Bower, 1995, Early enteral administration of a formula (impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial, Crit Care Med, 23, 436, 10.1097/00003246-199503000-00006

Alexander, 1995, Specific nutrients and the immune response, Nutrition, 11, 229

Parrillo, 1991, Management of septic shock present and future, Ann Intern Med, 115, 491, 10.7326/0003-4819-115-6-491

Ziegler, 1982, Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant, Escherichia coli. N Engl J Med, 307, 1225, 10.1056/NEJM198211113072001

J. Study Group, 1992, Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study, J Infect Dis, 165, 695, 10.1093/infdis/165.4.695

Calandra, 1988, Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind randomized trial, J Infect Dis, 158, 312, 10.1093/infdis/158.2.312

Baumgartner, 1985, Prevention of Gram-negative shock and death in surgical patients by an antibody to endotoxin core glycolipid, Lancet, ii, 59, 10.1016/S0140-6736(85)90176-X

McCutchen, 1983, Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, Gram-negative infections in patients with prolonged neutropenia, SchweizMed Wochenschr, 113, 40

Golenbock, 1988, Lipid X protects mice against fatal Escherichia coli infection, Infect Immun, 56, 779, 10.1128/iai.56.4.779-784.1988

Chase, 1986, Effect of monophosphoryl lipid A on host resistance to bacterial infection, Infect Immun, 53, 711, 10.1128/iai.53.3.711-712.1986

Astiz, 1991, Monophosphoryl lipid A induces tolerance to lethal hemodynamic effects of endotoxemia, Circ Shock, 33, 92

Nakamura, 1995, Effects of pretreatment with SDZ MRL 953, a novel imunostimulatory lipid A analog, on endotoxin-induced acute lung injury in guinea pigs, Clinical and Diagnostic Laboratory Immunology, 2, 672, 10.1128/cdli.2.6.672-677.1995

Greenman, 1991, A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group, JAMA, 266, 1097, 10.1001/jama.1991.03470080067031

Bone, 1995, A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group, Crit Care Med, 23, 994, 10.1097/00003246-199506000-00003

Ziegler, 1991, Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind placebo-controlled trial. The HA-1A Sepsis Study Group, N Engl J Med, 324, 429, 10.1056/NEJM199102143240701

Warren, 1992, Anti-endotoxin monoclonal antibodies, N Engl J Med, 326, 1153, 10.1056/NEJM199204233261711

Abraham, 1995, Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-α MAb Sepsis Study Group, JAMA, 273, 934, 10.1001/jama.1995.03520360048038

Van Zee, 1992, Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-a in vitro and in vivo, Proc Natl Acad Sci USA, 89, 4845, 10.1073/pnas.89.11.4845

Reinhart, 1996, Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study, Crit Care Med, 24, 733, 10.1097/00003246-199605000-00003

Mohler, 1993, Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists, J Immunol, 151, 1548, 10.4049/jimmunol.151.3.1548

Fisher, 1996, Treatment of septic shock with the tumor necrosis factor receptor :Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group, N Engl J Med, 334, 1697, 10.1056/NEJM199606273342603

Aiura, 1991, Interleukin-1 receptor antagonist blocks staphylococcal induced septic shock in rabbits, Cytokine, 3, 498, 10.1016/1043-4666(91)90337-D

Eisenberg, 1990, Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist, Nature, 343, 341, 10.1038/343341a0

Hannum, 1990, Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor, Nature, 343, 336, 10.1038/343336a0

Fisher, 1994, Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-lra Sepsis Syndrome Study Group, JAMA, 271, 1836, 10.1001/jama.1994.03510470040032

Knaus, 1996, Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-lra Phase III Sepsis Syndrome Study Group, Crit Care Med, 24, 46, 10.1097/00003246-199601000-00010

Bone, 1987, A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock, N Engl J Med, 317, 653, 10.1056/NEJM198709103171101

The, 1987, Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis, N Engl J Med, 317, 659, 10.1056/NEJM198709103171102

Sprung, 1984, The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study, N Engl J Med, 311, 1137, 10.1056/NEJM198411013111801

Hinshaw, 1986, Effects of prior administration of steroids upon recovery from lethal sepsis, Surg Gynecol Obstet, 163, 335

Taffet, 1989, Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP, Cell Immunol, 120, 291, 10.1016/0008-8749(89)90198-6

Strieter, 1988, Cellular and molecular regulation of tumor necrosis factor-cz production by pentoxifylline, Biochem Biophys Res Commun, 155, 1230, 10.1016/S0006-291X(88)81271-3

Schade, 1990, Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor, Circ Shock, 31, 171

Giroir, 1992, Effect of amrinone on tumor necrosis factor production in endotoxin shock, Circ Shock, 36, 200

Graninger, 1995, Pentoxifylline in severe inflammatory response syndrome, J Cardiovasc Pharmacol, 25, S134-8, 10.1097/00005344-199500252-00028

Zeni, 1996, Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study, Crit Care Med, 24, 207, 10.1097/00003246-199602000-00005

Oismuller, 1995, In vitro modulation of human neutrophil function by pentoxifylline in patients with septic syndrome, Shock, 4, 161, 10.1097/00024382-199509000-00002

de Felippe, 1993, Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1–3 polyglucose (glucan), Surg Gynecol Obstet, 177, 383

Babineau, 1994, Randomized Phase 1/11 trial of macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients, Ann Surg, 220, 601, 10.1097/00000658-199411000-00002

Willatts, 1995, Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled double-blind trial, Crit Care Med, 23, 1033, 10.1097/00003246-199506000-00007

Lefer, 1989, Significance of lipid mediators in shock states, Circ Shock, 27, 3

Harlan, 1985, Septic Shock. Contemporary Issues in Infectious Diseases. Vol. 4, 83

Reines, 1982, Plasma thromboxane concentrations are raised in patients dying with septic shock, Lancet, ii, 174, 10.1016/S0140-6736(82)91027-3

Kettelhut, 1987, The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors, Proc Natl Acad Sci USA, 84, 4273, 10.1073/pnas.84.12.4273

Fink, 1988, Systemic and regional hemodynamic effects of cyclo-oxygenase and thromboxane synthetase inhibition in normal and hyperdynamic endotoxemic rabbits, Circ Shock, 26, 41

Jacobs, 1982, Ibuprofen in canine endotoxin shock, J Clin Invest, 70, 536, 10.1172/JCI110645

Haupt, 1989, Effects of ibuprofen in patients with severe sepsis syndrome, Chest, 96, 291s

Smith, 1988, Beneficial effects of the peptidoleukotriene receptor antagonist, SK and F 104353, on the responses to experimental endotoxemia in the conscious rat, Circ Shock, 25, 21

Byrne, 1990, Increased survival time after delayed histamine and prostaglandin blockade in a porcine model of severe sepsis-induced lung injury, Crit Care Med, 18, 303, 10.1097/00003246-199003000-00012

Turner, 1990, Therapeutic intervention in a rat model of ARDS. I. Dual inhibition of arachidonic acid metabolism, Circ Shock, 32, 231

Dhainaut, 1994, Platelet-activating factor receptor antagonist BS 52021 in the treatment of severe sepsis: a randomized double-blind, placebo-controlled multicenter clinical trial. BN 52021 Sepsis Study Group, Crit Care Med, 22, 1720, 10.1097/00003246-199422110-00005

Ridings, 1995, Beneficial effects of a bradykinin antagonist in a model of Gram-negative sepsis, J Trauma, 39, 81, 10.1097/00005373-199507000-00011

Bone, 1996, Sir Isaac Newton, sepsis, SIRS, and CARS, Crit Care Med, 24, 1125, 10.1097/00003246-199607000-00010

Bone, 1996, Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and 'the multiple organ dysfunction syndrome (MODS), Ann Intern Med, 125, 680, 10.7326/0003-4819-125-8-199610150-00009

Bone, 1996, Why sepsis trials fail, JAMA, 276, 565, 10.1001/jama.1996.03540070061032